JANX

Janux Therapeutics, Inc.

Janux Therapeutics, Inc. (JANX) has 9 SEC Form 4 filings (9 transaction rows) in the rolling window, disclosed by 1 distinct insider. Most recent filing: Jul 11, 2026.

  • Industry:Biotechnology
  • CEO:David Alan Campbell
  • Employees:91
  • HQ:San Diego, CA, US
  • IPO:2021-06-11

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$57K

reported sales (SEC code S)

Unique Insiders

1

in the rolling window

Market Cap

$966.0M

latest known value

Source
Doyle Janeen NoelFirst filing
Sale$57KJun 5SEC ↗

Related companies

Janux Therapeutics, Inc. is in the Healthcare sector.